iPSC-derived T-cell therapy (Notch Therapeutics)

N/A

Report date: 2025/03/20 16:04:45

Base Information

Drug NameiPSC-derived T-cell therapy (Notch Therapeutics)
Drug Alias NameInduced pluripotent stem cell derived Cytotoxic T Cells (Notch Therapeutics)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocytes modulators
TargetsUpdating
Therapy Area/IndicationsSolid tumoursHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNotch Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesNotch Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A